Product Description
Mechanisms of Action: Bile Acid Analogue
Novel Mechanism: Yes
Modality: Nondrug
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Norgine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Liver Cirrhosis
Phase 2: Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis|Liver Cirrhosis, Alcoholic|Fatty Liver, Alcoholic|Hepatitis A
Phase 1: Healthy Volunteers|Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NRL972 in chronic heptatitis | N/A |
Completed |
Hepatitis B, Chronic |
2011-09-30 |
|
| NRL972 in patients attempting alcohol cessation | P2 |
Completed |
Unknown |
2011-01-21 |
|
| NRL972-01/2010 (AMET) | P1 |
Completed |
Liver Cirrhosis |
2010-11-01 |
|
| NRL972-01/2007 (FLD) | P2 |
Completed |
Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2010-03-01 |